ACP supports QPP measure 412: "Documentation of Signed Opioid Treatment Agreement because it protects clinicians from the repercussions of patients who violate the opioid agreement. Also, considering the magnitude and urgency of the opioid epidemic, quality programs should adopt this measure unless data is otherwise available to describe the negative consequences of this measure. While we support this measure, we suggest the developers update the measure specifications to include appropriate exclusion criteria for patients receiving active cancer treatment, and patients receiving palliative and end-of-life care."